Auto-Injectors Market

Auto Injectors Market to Exceed US$2.5 bn by 2020
Auto Injectors Market is poised to log a CAGR of 18.6% from 2014 to 2020.
Driven by the rising incidence of conditions such as anaphylaxis in developed countries and the
creation of a favorable reimbursement scenario by governments across the world, the global auto
injectors market is poised to log a CAGR of 18.6% from 2014 to 2020. These findings are
published in Transparency Market Research’s study, titled ‘Auto-Injectors Market - Global Industry
Analysis, Size, Share, Growth, Trends and Forecast, 2014 - 2020’.
Read Report overview @
The study states that the global auto-injectors market will rise from its 2013 valuation of US$665.0
mn to rise to US$2.5 bn by 2020, with enormous opportunities existing in RoW markets and
emerging economies. An alarming increase in the prevalence of rheumatoid arthritis and various
food allergies will further create opportunities for the growth of the auto injectors market globally.
TMR analysts identify a major roadblock standing in the way of companies trying to occupy a
larger revenue share in the auto-injectors market: The high prices of auto-injectors. The price factor
assumes greater importance when it comes to patients in emerging economies, where, incidentally,
the most lucrative growth opportunities lie.
Even so, the demand for auto injectors will continue to rise consistently as patients opt to choose
these products for their ease of use, even during self-administration. The report segments the global
auto injectors market on the basis of product type, manufacturing design, therapeutic application,
and geography. On the basis of product type, the market is segmented into prefilled or disposable
auto injectors and fillable or reusable auto injectors. Given their unmatched ease of use, pre-filled
auto injectors made up the largest segment in the auto injectors market by product type.
Likewise, using manufacturing design as a criterion, the global auto-injectors market has been
segmented into customized and standardized auto injectors. Although the standardized injectors
segment was the larger one in 2013, the growth of the customized auto-injectors segment will be the
fastest through the report’s forecast period.Moving further, the report segments the auto-injectors
market by therapeutic application into anaphylaxis, rheumatoid arthritis, multiple sclerosis, and
others. The high prevalence of anaphylaxis has created a massive demand for auto injectors for
administrating drugs to people suffering from this condition. This factor has made the anaphylaxis
the largest application segment in the auto injectors market.
Request Sample [email protected]
From the geographical standpoint, the market for auto injectors is segmented into North America,
Asia Pacific, Europe, and Rest of the World (RoW). Claiming a 70% stake in the global autoinjectors market, North America was seen to be the largest regional market in 2013. While the
dominant position of North America will not see a drastic change, the Asia Pacific market will
report the fastest rate of growth. The key recommendations of TMR’s analysts, discussed in detail in
the report, include: Channeling investments into China and India, spearheading innovation in auto
injectors, and improving consumer awareness through marketing campaigns.
Companies profiled in detail in the auto-injectors market report include: Pfizer, Inc., Becton,
Dickinson & Co., Mylan, Inc., Antares Pharma Inc., Novartis International AG, Unilife Corp.,
Ypsomed Holding AG, Biogen Idec, and Scandinavian Health Ltd.